{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-065623","form_type":"8-K","ticker":"ICU","cik":"0001831868","company_name":"SeaStar Medical Holding Corp","filed_at":"2023-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.849042+00:00","generated_at":"2026-06-07T22:21:17.682058+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SeaStar Medical Q3 net loss $7.4M; FDA Approvable Letter for pediatric AKI device received","bullets":["Net loss $7.4M ($0.37/share) vs $1.9M ($0.26/share) YoY; no revenue as pre-commercial stage.","Cash $73,000 at Sep 30, raised $3.5M convertible notes in Aug-Sep 2023.","Received FDA Approvable Letter for SCD-PED; formal approval expected Dec 2023-Jan 2024.","Breakthrough Device Designation granted for cardiorenal and hepatorenal syndromes in Sep-Oct 2023.","NEUTRALIZE-AKI adult trial enrolled 7 patients; target 200 at up to 30 U.S. sites."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-065623","json":"https://secwatch.observer/filing/0000950170-23-065623.json","markdown":"https://secwatch.observer/filing/0000950170-23-065623.md","text":"https://secwatch.observer/filing/0000950170-23-065623.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/0000950170-23-065623-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/icu-20231121.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:21:17.682058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5a798d90652c8527fed3eb110b844dc1fd28da4","claim":"SeaStar Medical Holding Corp reported financial results for three and nine months ended September 30, 2023.","evidence_excerpt":"reports financial results for the three and nine months ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831868/000095017023065623/0000950170-23-065623-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}